Table 2.
Comparing CTC status, CTC count, and PFS and OS between subgroups defined by specific patterns of tumor subtype conversion.
| Statistics | Total, n (%) | CTC Positive, n (%) | CTC Count, Median (Range) | PFS, Median (Range) | OS, Median (Range) |
|---|---|---|---|---|---|
| Receptors (PT > MT) | |||||
| ER + HER2 Ø > ER + HER2 Ø | 138 (100%) | 53 (38.4%) | 1 (0–200,000) | 6 (1–76) | 20.5 (0–94) |
| ER Ø HER2 Ø > ER Ø HER2 Ø | 35 (100%) | 14 (40%) | 1 (0–74) | 4.5 (0–18) | 11 (0–94) |
| ER + HER2 + > ER Ø HER2 Ø | 19 (100%) | 8 (42.1%) | 3 (0–840) | 5 (0–19) | 10 (0–29.5) |
| HER2 + > HER2 + | 35 (100%) | 3 (8.6%) | 0 (0–100) | 4 (0–26) | 15 (0–92) |
| HER2 Ø > HER2 + | 17 (100%) | 5(29.4%) | 0 (0–91) | 7 (1–30) | 29 (4–55) |
| ER Ø HER2 + > ER + HER2 Ø | 9 (100%) | 4(44.4%) | 0 (0–840) | 4.5 (2–14) | 7 (3–43) |
| ER Ø HER2 Ø > ER + HER2 Ø | 8 (100%) | 3(37.5%) | 3 (0–22) | 3 (1–32) | 21 (0–55) |
| p | 0.04 | 0.23 | 0.6 | 0.07 |
Ø—negative; ER—estrogen receptor; HER2—human epidermal growth factor receptor 2.